Nidogen-2 (NID2) is a key component of the basement membrane that stabilizes the extracellular matrix (ECM) network. The aim of the study is to analyze the functional roles of NID2 in the pathogenesis of nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). We performed genome-wide methylation profiling of NPC and ESCC and validated our findings using the methylation-sensitive high-resolution melting (MS-HRM) assay. Results showed that promoter methylation of NID2 was significantly higher in NPC and ESCC samples than in their adjacent non-cancer counterparts. Consistently, down-regulation of NID2 was observed in the clinical samples and cell lines of both NPC and ESCC. Re-expression of NID2 suppresses clonogenic survival and migration abilities of transduced NPC and ESCC cells. We showed that NID2 significantly inhibits liver metastasis. Mechanistic studies of signaling pathways also confirm that NID2 suppresses the EGFR/Akt and integrin/FAK/PLCγ metastasis-related pathways. This study provides novel insights into the crucial tumor metastasis suppression roles of NID2 in cancers.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5346683 | PMC |
| http://dx.doi.org/10.18632/oncotarget.12889 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
First-line immune checkpoint inhibitors in low programmed death-ligand 1-expressing population.
Front Pharmacol
July 2024
Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.
Article Synopsis
- * A study analyzed data from 34 trials to compare the effectiveness of PD1/PD-L1 inhibitors versus standard treatments for patients with low PD-L1 expression (< 1%), revealing that combination therapies provided significant survival benefits over standard care, especially in non-small cell lung cancer and other specific cancers.
- * Overall, anti-PD-1/PD-L1 combination therapy improved overall survival (OS) and progression-free survival (PFS) compared to standard treatment, while monotherapy results were
CircNRIP1: An emerging star in multiple cancers.
Pathol Res Pract
January 2023
College of Basic Medical Science, China Three Gorges University, Yichang 443002, China. Electronic address:
Circular RNAs (circRNAs) are a new class of non-coding RNAs (ncRNAs) with a closed-loop structure that is highly stable and widely present in the eukaryotic cytoplasm. In recent years, circRNA has played a non-negligible role in the occurrence and development of a variety of diseases, which has attracted the research attention of many scholars. Circular RNA nuclear receptor interacting protein 1 (circNRIP1), a newly discovered circRNA, has been confirmed to be closely associated with cervical carcinoma (CC), colorectal cancer (CRC), esophageal squamous cell carcinoma (ESCC), gastric cancer (GC), nasopharyngeal carcinoma (NPC), non-small cell lung cancer (NSCLC), osteosarcoma (OS), ovarian cancer (OC) and papillary thyroid carcinoma (PTC).
View Article and Find Full Text PDFThe survival impact of postoperative complications after curative resection in patients with esophageal squamous cell carcinoma: propensity score-matching analysis.
J Cancer Res Clin Oncol
May 2020
Department of Gastroenterological Surgery, National Kyushu Cancer Center, 3-1-1 Notame, Minami-ku, Fukuoka, 811-1395, Japan.
Purpose: The relationship between postoperative complications and long-term survival after surgery for esophageal squamous cell carcinoma (ESCC) is controversial.
Method: A total of 210 patients with ESCC who underwent subtotal esophagectomy with a reconstructed gastric tube were investigated according to the development of postoperative complications. The associations of age, gender, T and N factors, and pStage with grade 0-2 complications (NSC) and grade 3 and higher complications (SC) were compared by propensity score-matching analysis.
Epigenomic characterization of a p53-regulated 3p22.2 tumor suppressor that inhibits STAT3 phosphorylation via protein docking and is frequently methylated in esophageal and other carcinomas.
Theranostics
November 2018
Cancer Epigenetics Laboratory, Department of Clinical Oncology, State Key Laboratory of Oncology in South China, Sir YK Pao Center for Cancer and Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong.
Oncogenic STAT3 signaling activation and 3p22-21.3 locus alteration are common in multiple tumors, especially carcinomas of the nasopharynx, esophagus and lung. Whether these two events are linked remains unclear.
View Article and Find Full Text PDFChemoradiotherapy for Synchronous Multiple Primary Cancers with Esophageal Squamous Cell Carcinoma: a Case-control Study.
J Cancer
February 2017
Departments of Radiation Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Article Synopsis
- The study assessed the effectiveness and side effects of concurrent chemoradiotherapy (CRT) in patients with esophageal squamous cell carcinoma (ESCC) who also had multiple primary cancers (MPC) in the upper digestive tract, comparing them with patients who only had non-multiple primary cancers (NPC).
- Results showed that while most patients completed treatment, those with MPC experienced significantly lower survival rates and higher severe side effects, particularly radiation esophagitis and mucositis, compared to the NPC group.
- The findings suggest that concurrent CRT may be less effective for patients with MPC and highlight the need for further research to understand this discrepancy and improve treatment methods, potentially through advanced radiation techniques.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!